In an interview conducted during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress, Daniel AuClair, PhD, the Chief Scientific Officer for the Multiple Myeloma Research Foundation, in Norwalk, CT, discusses novel agents for the treatment of patients with multiple myeloma. He discusses the use of immunotherapies, including the FDA-approved CAR T-cell therapy, idecabtagene vicleucel, and the possible future approval of ciltacabtagene autoleucel.